MB49-derived cancer stem cell antigens (MB49-CSC antigens)

MB49-derived cancer stem cell antigens represent a heterogeneous pool of proteins and molecules specifically expressed by the cancer stem cell (CSC) subpopulation of the MB49 mouse bladder cancer cell line (Pan et al., 2015). These antigens are associated with the unique properties of CSCs, including self-renewal, high tumorigenicity, and resistance to conventional therapies like chemotherapy and radiation (Lu et al., 2011). Common markers identified within this antigenic pool include CD44, CD133, and ALDH1, which serve as functional drivers of the stem-like phenotype (He et al., 2011). In therapeutic contexts, these antigens are utilized to develop dendritic cell (DC) vaccines, where DCs are pulsed with CSC lysates or mRNA to prime the immune system against the tumor-initiating subpopulation. The primary biological role of these antigens in the disease state is to maintain the tumor's regenerative capacity and facilitate immune evasion. Targeting these antigens aims to induce a robust cytotoxic T lymphocyte (CTL) response that can specifically recognize and eliminate CSCs, thereby preventing tumor recurrence and metastasis (Zhang et al., 2017). Research indicates that vaccines targeting these antigens can significantly inhibit tumor growth and prolong survival in preclinical bladder cancer models compared to vaccines targeting bulk tumor cells.

Other names

MB49 cancer stem cell-associated antigensMB49 CSC lysateBladder cancer stem cell antigens (MB49-derived)MB49-CSC-enriched antigens

Induction of a specific cytotoxic T lymphocyte (CTL) response and Th1-biased immune response against cancer stem cell populations, leading to the targeted elimination of tumor-initiating cells and inhibition of tumor growth (Pan et al., 2015).